Radiation Applications

Radioisotopes / Cancer Institute And NRG Highlight Concerns Over Long-Term Lu-177 Supplies

By David Dalton
7 June 2021

Report points to ‘lack of central planning’ and need for more facilities
Cancer Institute And NRG Highlight Concerns Over Long-Term Lu-177 Supplies
The high flux research reactor at Petten in the Netherlands. Courtesy NRG.
New cancer treatments are being developed using the radioisotope lutetium-177 (Lu-a77), but production will need to be scaled up and the threat of potential shortages dealt with alongside continued investment in new irradiation facilities.

Want to know more?
Sign up.

Pen Use this content

Tags


Related